Poseltinib clinical trials
Also written LY3337641.
How each study uses poseltinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the poseltinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LY3337641
- 2
Studies by the year they started
8 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 2
Eli Lilly and Company (4) · Seoul National University Hospital (2) · Hanmi Pharmaceutical Company Limited (1) · NOBO Medicine (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test poseltinib.
- Dec 2026NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's LymphomaPhase 1 · NOBO Medicine
Studies
Open first, then newest update. How each study uses poseltinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's LymphomaRecruitingPhase 1NOBO MedicineNCT07114367Written as NB02 (Poseltinib)
- Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell LymphomaNot yet recruitingPhase 1/2Seoul National University HospitalNCT07269639Written as Golcadomide + Poseltinib + Rituximab
- GPL in Patients with Relapsed/refractory Diffuse Large B Cell LymphomaActive, not recruitingPhase 2Seoul National University HospitalNCT05335018Written as Glofitamab, Poseltinib, Lenalidomide
- A Study of LY3337641 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT03099148Written as LY3337641 (T1)
- A Study of LY3337641 in Healthy Male ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT02914379Written as [¹⁴C]-LY3337641
- A Study of LY3337641 in Japanese and Caucasian Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT03083561Written as LY3337641
- A Study of LY3337641 in Rheumatoid ArthritisTerminatedPhase 2Eli Lilly and CompanyNCT02628028Written as LY3337641
- Safety,PK/PD, Food Effect Study of Orally Administered HM71224 in Healthy Adult Male VolunteersCompletedPhase 1Hanmi Pharmaceutical Company LimitedNCT01765478Written as HM71224 single ascending dose
Codes
What other systems call poseltinib · ClinicalTrials.gg INT001775
- MeSH (NLM) C000720850poseltinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) D01E4B1U35POSELTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27275916poseltinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C141273PoseltinibOne source FDA
- DrugBank DB16299One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720850 | poseltinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | D01E4B1U35 | POSELTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27275916 | poseltinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C141273 | Poseltinib | One source FDA |
| DrugBank | DB16299 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.